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Purpose: To review studies which support the hypothesis that allograft inflammatory factor-1 (AIF-1), a protein initially identified in chronically rejected cardiac allografts, may be involved in the pathogenesis of the progressive fibroproliferative vasculopathy which is a hallmark of systemic sclerosis (SSc). 
Recent findings:  Recent findings demonstrated elevated AIF-1 expression both in SSc affected tissues and peripheral blood mononuclear cells.  A detailed immunohistopathologic study examined the tissue and cellular localization of the protein in affected SSc tissues and demonstrated its expression in the endothelium of dermal and pulmonary vessels, in the pulmonary parenchyma, and in relevant inflammatory cells including T cells and macrophages.  Furthermore, functional studies showed specific AIF-1 isoform expression stimulation by TGF-.








Systemic Sclerosis (SSc) is a disease of unknown etiology characterized by progressive fibrosis of the skin, the microvasculature, and numerous internal organs.  The pathogenesis of SSc is extremely complex and, at present, there is no single unifying hypothesis which explains the characteristic triad of pathologic changes in the disease: 1) severe and often progressive cutaneous and visceral fibrosis, 2) obliteration of the lumen of small arteries and arterioles, and 3) humoral and cellular immunologic abnormalities which include the production of numerous autoantibodies, chronic mononuclear cell infiltration of affected tissues, and dysregulation of lymphokine and growth factor production (1, 2).  At present, it is not clear which of these alterations is of primary importance or how they interrelate to cause the progressive fibrotic process in SSc and numerous studies have searched for potential molecular candidates which may bridge these three co-existing pathogenetic processes.   We believe that the novel protein, allograft inflammatory factor-1 (AIF-1), may be one of these molecular candidates which deserves to be studied as a potentially important mediator in the development of SSc vasculopathy.   This protein was first identified in rat cardiac allografts undergoing chronic rejection (3) and its mRNA was found to be upregulated during macrophage adhesion and infiltration into the neointima of affected vessels (4). This upregulation was evident even before the vascular smooth muscle cell accumulation in the vessel wall indicating that AIF-1 was intimately involved in the early events that precede the severe and progressive vessel narrowing which is the characteristic of chronic cardiac allograft rejection vasculopathy.  There are remarkable similarities in the pathogenesis and in the histopathologic appearance of chronic cardiac allograft rejection vasculopathy and those of the vascular alterations observed in SSc.  For example, immunologic mechanisms and persistent tissue infiltration with macrophages and lymphocytes, diffuse concentric intimal proliferation, vascular smooth muscle cell (VSMC) proliferation and vessel wall fibrosis are found in both entities.  These striking similarities provide a strong rationale and vastly justify the study of the possible role of AIF-1 in the pathogenesis of SSc.

ALLOGRAFT INFLAMMATORY FACTOR -1 (AIF-1)   
AIF-1 is a novel protein first identified in rat cardiac allografts undergoing chronic rejection (3). AIF-1 has been found to be selectively expressed in macrophages and neutrophils (4) and more recently also in T cells (5).  AIF-1 expression has also been found in inflammatory lesions of the central nervous system and in pancreatitis of pre-diabetic rats. These observations collectively suggest that AIF-1 has a close association with chronic inflammatory processes such as those occurring in SSc patients.   Despite intense recent study, AIF-1 function, its role in inflammatory cell activation, or the identity of the molecular pathways involved are not known.  Philogenetic studies showed that AIF-1 is a protein conserved across distant evolutionary boundaries being present from sea sponges to humans (6).  Interestingly, the sea sponge (the simplest organism capable of organ rejection in the philogenetic hierarchy) is the first organism to show AIF-1 in the genome. Of further interest is the striking conservation in the gene sequence between sea sponges and humans with a 70% sequence homology, a value much higher than that observed for many other genes shared between these species.   In the human genome, AIF-1 is located close to the TNF- locus in the HLA class III region on the short arm of chromosome 6.  The gene spans 1800 nucleotides and encodes six different exons which are differentially spliced to produce three different isoforms or splicing variants (7) (Figure 1).  All three isoforms share a leucine zipper motif that suggests possible dimerization of the corresponding proteins.  The shortest isoform, isoform-1, has just a few more amino acid residues than the leucine zipper and lacks any recognized conserved regions suggesting a specific functional role perhaps as a decoy-binding isoform.  Isoform 2 shares the NH terminus with isoform 1 but is the only one expressing a specific exon upstream to the leucine zipper motif and a specific CH terminus. This isoform also comprises long 5’ and 3’ untranslated regions.  Isoform 3 is the longest and most extensively characterized variant coding for a 17 kD polypeptide. It has a specific NH terminus compared to isoforms 1 and 2 and contains two EF-hand Ca++ binding domains, recently found to be necessary for the activating function of the protein on VSMCs (8). 
	Seven single nucleotide polymorphisms (SNP) have been found in the introns and exons of AIF-1, however, not all are present in all isoforms (Figure 1).  Three SNPs cause an amino acid change in isoforms 2 and 3. The SNP, RS2269475, results in a non-synonymous change from tryptophan (W) to arginine (R) and is unique to exon 4 of isoform 2.  The SNP, RS2736182, results in a non-synonymous change from glycine (G) to arginine (R) unique to exon 3 in isoform 3, and the SNP, RS13195276, results in a non-synonymous change from phenylalanine (F) to serine (S), and is unique to exon 4 of isoform 2.  One other SNP is associated with this non-synonymous SNP in isoform 2 and is localized at the 3’ end of the isoform 2 specific promoter. 
Most of the published AIF-1 literature has focused on the complex molecular biology of its gene, and on the identification of its function, in particular, its role in the neointimal proliferation typical of chronic cardiac allograft rejection. The initial functional studies identified macrophages as the main source of AIF-1 expression (9) and demonstrated that AIF-1 was an INF- inducible gene which in turn could upregulate the expression of several cytokines including IL6, IL10 and IL12 in murine macrophages (10). Autieri et al. demonstrated that AIF-1 overexpression in VSMC was sufficient to promote migration and proliferation of human VSMC cell lines (11-14). Subsequent studies demonstrated that AIF-1 is also expressed in T cells (5,15,16) and that VSMCs, which do not express AIF-1 in vivo, could acquire an activated phenotype upon exposure to T cell supernatants overexpressing AIF-1, an effect which was G-CSF dependent (17).   Interestingly, the overexpression of AIF-1 isoform 2 or 3 in the same VSMC line had opposite effects on cell activation, suggesting that the molecular biology of AIF-1 was more complex than expected (18).  Altogether the data published during the decade that followed the identification and cloning of AIF-1 showed that the protein is not only a marker of the early inflammatory phenomena that precede neointima formation and lumen obliteration secondary to an immune challenge as it occurs in allograft rejection, but that it may also actually play a key regulatory role in this process.

AIF-1 AND SYSTEMIC SCLEROSIS
	Although numerous studies have examined the role of AIF-1 in the pathogenesis of cardiac allograft rejection vasculopathy and substantial insights have been gained regarding its function and some of the molecular mechanisms of its actions in the setting of cardiac transplant rejection, there is very little information about the potential involvement of the protein in SSc pathogenesis.
	AIF-1 polymorphisms in SSc.  There is strong evidence supporting the contribution of genetic factors in the development and expression of SSc.  Recent studies have examined mutations or polymorphisms in numerous genes relevant to SSc pathogenesis which may result in their increased or abnormal expression or may provide a genetic predisposition to the development of the disease.  An interesting study which pioneered the investigation of the role of AIF-1 in the pathogenesis of SSc examined the potential influence of AIF-1 polymorphisms on the expression of the disease (19).  These results showed a remarkable association between certain AIF-1 polymorphisms and SSc.  The SNP in exon 4A, which generates a non-synonymous change, was significantly associated with both DcSSc and LcSSc (P<0.0001 and P = 0.0048, respectively).  The intron 2A allele was also found to be associated with SSc (35.5% vs. 22.8%; P=0.01) and a trend for an increase in the exon 3T allele (P=0.07) was also observed.  The intron 2A allele was in linkage disequilibrium with the exon 4A allele (P=0.001) and with the intron 4T allele (P=0.02).  Thus, these studies showed that polymorphisms in the AIF-1 gene displayed a highly significant correlation with SSc.  
	AIF-1 gene expression in SSc skin.  The study of AIF-1 transcript expression in SSc showed that AIF-1 was strongly expressed in active SSc lesions. Skin biopsies from untreated SSc patients with disease of recent onset showed an average 14-fold higher mRNA expression of total AIF-1 than normal controls (20).  These results were confirmed by a separate microarray analysis of differentially expressed genes between peripheral blood mononuclear cells (PBMC) from SSc patients compared to normal controls.  These studies identified AIF-1 as one of the genes most overexpressed compared to normal controls (21).
	AIF-1 protein expression in SSc tissues.  A recent study performed an extensive immunohistopathological evaluation of the patterns of tissue expression of AIF-1 in SSc (20).  At the protein level AIF-1 was highly expressed in lesional SSc skin, both in endothelial cells and in CD3 cells infiltrating the dermis although not all CD3+ cells expressed AIF-1 (Figure 2).  AIF-1+/CD3+ cells were localized surrounding small arterioles in the upper dermis and subdermis.  Approximately 80% of CD3+ cells infiltrating the skin were found to express AIF-1.  In contrast, myofibroblasts, another key cell type in SSc skin pathology did not express the molecule at all (Figure 2).
	AIF-1 expression was also examined in the lungs from one patient who had died of pulmonary hypertension secondary to SSc and from two patients who had SSc-associated pulmonary fibrosis. All specimens showed strong AIF-1 expression. The samples from the patient with pulmonary hypertension showed a very strong staining for AIF-1 in small arterioles and all vessel layers but the staining was very pronounced in the endothelium and subendothelium of partially or completely occluded vessels (Figure 3). Lung biopsies from patients with pulmonary fibrosis secondary to SSc showed strong staining in the cells infiltrating the parenchyma and in the fibrotic interstitium. In contrast, normal lung showed negligible AIF-1 expression, which was limited to resident tissue macrophages.  The expression of AIF-1 in smooth muscle cells was investigated by co-staining lung tissues with -smooth muscle actin (-SMA) and AIF-1. Numerous AIF-1+ cells were observed within the vessel wall (Figure 3), many of them accumulating in areas of vessel wall narrowing; however, there was no co-localization of AIF-1 with -SMA in any of the cells indicating that in SSc lung, mature, fully differentiated VSMC do not express AIF-1. There was also no co-localization of -SMA and AIF-1 in activated fibroblasts.
	The inflammatory cells within SSc lungs that expressed AIF-1 protein were identified by double label immunohistochemistry for CD1a and AIF-1, CD68 and AIF-1, CD3 and AIF-1, or CD20 and AIF-1. A strong expression of AIF-1 was observed in CD68+ cells, CD3+ (T cells) and CD1a+ (dendritic cells) but not in CD20+ cells (B cells).  Of great relevance was the observation that in addition to the infiltrating inflammatory cells microvascular endothelial cells identified as CD31+ (PECAM-1) cells in the inner layer of the vessel were also strongly positive for AIF-1.
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Figure 1.  Scheme of AIF-1 gene splicing variants.   Boxes represent exons, lines represent introns. Red boxes: untranslated regions; Blue boxes: protein coding regions. Arrowheads: AU rich elements in the 3’ UTR. The vertical dotted lines underline the common sequences among the isoforms.
Figure 2. Immunofluorescence microscopy of SSc skin. Tissue sections were stained for either AIF-1 alone, or both -SMA and AIF-1 (AIF-1, FITC channel-GREEN; -SMA, Cy3 channel-RED).  A: Epifluorescence images of the FITC channel for AIF-1 staining. Arrows indicate two small vessels.  Numerous fluorescent cells in the inner layer of the vessels and perivascular infiltrate are observed.  The positive cells of the inner layer of the vessel and the perivascular infiltrate have been identified as endothelial cells and T cells, respectively.  B: -SMA/AIF-1 dual staining merged image.  Cells that express-SMA do not express AIF-1.  Scale: 100 .
Figure 3.  SSc lung sections were dual-stained for either CD3 and AIF-1, or -SMA and AIF-1.  Each image is labeled with the name and the color of the antibody detected.  Top: CD3AIF-1 dual staining of SSc lung parenchyma.  Immunofluorescent images of the single channels are shown in the AIF-1 and CD3 panels.  In the MERGED panel both channels are visualized together. Arrows indicate some AIF-1+ cells in SSc lung parenchyma that are CD3+ as well.  Bottom: -SMA/AIF-1 dual staining of a SSc partially occluded pulmonary artery.  Immunofluorescent images of the single channels are shown in the AIF-1 and -SMA panels.  In the MERGED panel both channels are visualized together.  Note the expression of AIF in the endothelium and inflammatory cells within the vessel.  Also note that no AIF-1+ cells coexpress -SMA. Scale 100 .
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